Related references
Note: Only part of the references are listed.Bortezomib Sensitizes Human Renal Cell Carcinomas to TRAIL Apoptosis through Increased Activation of Caspase-8 in the Death-Inducing Signaling Complex
Alan D. Brooks et al.
MOLECULAR CANCER RESEARCH (2010)
TRAIL Resistance of Breast Cancer Cells Is Associated with Constitutive Endocytosis of Death Receptors 4 and 5
Yaqin Zhang et al.
MOLECULAR CANCER RESEARCH (2008)
Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis
Susan L. Kohlhaas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Exploiting the enhanced permeability and retention effect for tumor targeting
Arun K. Iyer et al.
DRUG DISCOVERY TODAY (2006)
Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells
AD Sanlioglu et al.
BMC CANCER (2005)
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina et al.
NATURE BIOTECHNOLOGY (2003)
Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity
GM Dubowchik et al.
BIOCONJUGATE CHEMISTRY (2002)
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
A Ashkenazi
NATURE REVIEWS CANCER (2002)
Hyperosmolarity reduces GLUT4 endocytosis and increases its exocytosis from a VAMP2-independent pool in L6 muscle cells
DL Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types
XD Zhang et al.
FEBS LETTERS (2000)
Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL
JL Bodmer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
H Maeda et al.
JOURNAL OF CONTROLLED RELEASE (2000)
Share Paper
